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  Abstract 
 
Celiac disease is a small intestinal immune-mediated enteropathy precipitated 
by exposure to gluten, a protein complex in the cereals wheat, barley and rye, 
in genetically susceptible people. Once considered an uncommon disorder 
restricted to children of European descent, it is now known to be one of the 
most common chronic diseases encountered in the Western world, with a 
serological prevalence of 1% that can be diagnosed at any age. Since it is so 
common much co-morbidity comprising malignant and non-malignant 
conditions will occur in association.  
Malignant complications particularly lymphoma were first described over 50 
years ago but the natural history and how commonly these occurred were 
unknown until relatively recently. Similarly, many non-malignant conditions 
were known to occur but initially the risks were unclear. It was not until the 
frequency of coeliac disease could be determined accurately in the community 
and population-based studies of morbidity and mortality in coeliac disease 
patients carried out in defined cohorts that these questions could be 
answered.  
My research into these aspects of coeliac disease began in 1971 and a body of 
35 of my publications spanning the years 1974 to 2018 on the morbidity and 
mortality of the disorder are presented in this thesis. I have introduced my 
research findings at many international and national meetings and these data  
have been influential in shaping the research agenda of other workers. One of 
my papers (Publication 9) published in Gut in 1989, was the most cited of all 
papers which appeared in the journal for that year. To date it has been cited 
1122 times. Information exists for 24 papers presented here and for these the 
total number of citations stands at 3,887. This excludes references to book 
chapters. Anecdotal evidence indicates frequent mentions in lectures and 
clinical practice.   
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Morbidity and mortality in coeliac disease 
A critical appraisal of 35 published works 
 Introduction 
Through the years I have researched many aspects of coeliac disease clinically 
and in the laboratory. I have selected a series of 35 publications that I have 
authored or co-authored on the morbidity and mortality of coeliac disease 
written between 1974 and 2018. Disorders contributing to morbidity and 
mortality in coeliac disease can be divided into malignant and non-malignant. 
Those due to malignancy particularly lymphoma, are the most serious. 
Fourteen of the publications are concerned primarily with this aspect while 21 
are devoted to non-malignant associations. This is a personal journey that 
highlights my own research but also reflects the evolution of thinking on these 
subjects over the last 45 years. 
Malignant associations 
In 1936, an association between idiopathic steatorrhoea (now regarded as 
coeliac disease) and lymphoma was recognised (1) and subsequently in 
numerous reports. In each instance it was assumed that steatorrhoea occurred 
secondarily to lymphoma. However, in 1962 workers from Bristol (2)  
suggested that lymphoma was a complication of coeliac disease and that the 
mucosal lesion in the upper small bowel was a premalignant condition. This 
concept was strengthened in further publications from Bristol (3) and 
Birmingham (4), both appearing in 1967.  
Malignant potential of coeliac disease (5) 
Because of the paucity of information available, I decided to review the original 
series created by Harries and his colleagues (4) consisting of 202 patients with 
coeliac disease diagnosed at the General and Queen Elizabeth Hospitals 
Birmingham, between 1941 and 1965, to determine how many further 
malignant tumours had arisen after a further 10 years had elapsed (5). A 
criticism of the series of Harris is that only 136 patients were confirmed as 
18 
 
Sensitivity: Internal 
having coeliac disease by small bowel biopsy while 66 were labelled as 
idiopathic steatorrhoea.  It is likely that this latter group did have coeliac 
disease because subsequently 10 had a biopsy which confirmed the diagnosis 
by histology. For the statistical analysis expected figures for malignant tumours 
were obtained by Harries and his colleagues from the Birmingham Cancer 
Registry, with over 95% registrations for a population in the area of 4.5 million 
people. In total, 77 patients had died and 31 malignancies occurred in 29 
patients of whom 14 had developed lymphoma and 6 carcinoma of the 
oesophagus. These were regarded as statistically significant results. It was not 
possible to decide the effect of a gluten free diet on the risk of malignancy 
because the data was inadequate. A criticism of this work is that patients were 
attending a secondary or even tertiary referral centre that would attract those 
patients with complications thus skewing the results. Also at that time it was 
not appreciated how many undiagnosed patients with coeliac disease there 
were in the community so the malignant risks were greatly overstated. 
Nevertheless, the high number of lymphomas arising in a relatively small 
number of patients indicated this was indeed a complication of coeliac disease. 
This suspicion was strengthened when I reviewed the series 10 years later (5). 
Another 20 patients had died (Table 1) and 4 more had developed lymphoma 
(Table 2).  
At this time, I identified another series of 210 patients diagnosed by small 
bowel mucosal biopsy in Birmingham up to the end of 1972 and followed up to 
the end of 1974 (5). When deaths from all malignancies were analysed, a 
significant increase occurred in all deaths from cancer in the whole series and 
in men and women separately. An increase was noted in deaths from 
lymphoma in men and women and in oesophageal and pharyngeal cancer in 
men (5) [Table 7]. A gluten free diet was not shown to reduce the prevalence 
of lymphoma. This series did take matters a step further because only biopsy 
diagnosed patients were included but there was still the issue that these were 
a selected group seen in a referral centre and many undiagnosed cases now 
known to be in the community did not come into the risk calculations because 
at that time these were not known about. Also, it was perhaps optimistic to 
expect to demonstrate any effect of a gluten free diet in patients who had 
already been exposed to an oncogenic stimulus, gluten, for many years, 
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probably since birth. This cohort of 210 patients was kept under careful review 
with the aim of a further analysis in future years (this was undertaken at the 
end of 1985 as detailed below). 
Clinical features of malignancy in coeliac disease (6) 
In the 1970s very little was known about the clinical manifestations of 
malignancy in coeliac disease particularly with regard to presentation, 
diagnosis and prognosis. Therefore at this time, we reviewed 55 patients with 
coeliac disease and malignancy, 27 with lymphoma and 28 with other cancers, 
who had been seen at the General Hospital Birmingham (6). That a lymphoma 
might have developed was suggested by deterioration in a patient previously 
stable on gluten free diet or who had not responded to diet from the outset. 
Weight loss, abdominal pain, diarrhoea, profound muscle weakness and fever, 
associated with anaemia, raised inflammatory markers, hypoalbuminaemia 
and steatorrhoea were important clinical features. The presentations of 
malignancies other than lymphoma were no different from those in non-
coeliac patients and their development did not provoke a relapse of coeliac 
disease. There were no features that allowed an early diagnosis of lymphoma 
to be made and investigations available at that time were largely unhelpful. 
Only two thirds of lymphomas were diagnosed during life. The prognosis for 
lymphoma was extremely poor with life expectancy measured in a few 
months. There was no effective treatment. How common these complications 
were was unknown because reliable epidemiological studies could not be 
carried out at this time. 
Malignancy in coeliac disease and the effect of a gluten free diet (7) 
The  series of 210 patients was again reviewed at the end of 1985 after a 
further 11 years of follow up (7). During this time 12 new cancers occurred of 
which 2 were lymphomas, a significant increase and 1 a carcinoma of the 
oesophagus (7) [Table 2].  This was further evidence that lymphoma does 
complicate coeliac disease. A two-fold risk of cancer was found and the excess 
was because of increased risk of cancers of the mouth, pharynx, oesophagus 
and non-Hodgkin's lymphoma. A 42.7-fold increased risk was found for non-
Hodgkin's lymphoma [Table 1). In order to explore any influence of diet on 
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cancer risk, the patients were grouped according to their adherence to a gluten 
free diet. Group 1 included those who had kept the diet strictly for 5 or more 
consecutive years. The 5-year period was an arbitrary time decided on before 
the analysis was carried out. This criterion was satisfied by 108 patients. Group 
2 consisted of 46 patients who had not taken a gluten free diet and Group 3 
was formed of 56 patients who had taken a gluten free diet for less than 5 
years and 39 who had only taken the diet sporadically. Because of the small 
numbers in Groups 2 and 3 these were combined for most of the analyses and 
designated Group 2. The risk of cancer over all sites was not significantly 
increased for those taking a strict gluten free diet (Group 1) but increased for 
those having a reduced gluten or normal diet (Group 2) [Table 3]. The 
occurrence of the two lymphomas accounted mainly for the small excess in 
Group 1. Patients in Group 2 showed an excess of cancers of the mouth, 
pharynx and oesophagus and also of lymphoma. Although no differences 
between the groups could be detected for individual sites, on combining them 
the differences between the relative risks, 6.7 (Group 1) and 38.6 (Group 2) 
was significant (p<0.05). When the results were distributed into the three 
original diet groups, a significantly decreasing trend in excess morbidity rates 
over increasing use of the gluten free diet was observed [Table 4].  
These results supported a protective role for a gluten free diet in guarding 
against lymphoma developing in coeliac disease. This was the first time that 
this had been demonstrated and the assertion has now been supported in at 
least 9 other studies so the proposition seems secure. This paper has been very 
influential and in the year of publication in 1989 in Gut, the Journal of the 
British Society of Gastroenterology, was the most quoted paper and was 
reproduced in a special edition of Gut to mark the Diamond Jubilee of the 
Society in 1997. It has since been cited on some 1118 occasions. 
This paper can be criticised in that the risk of malignancy and particularly 
lymphoma, is overstated, because the work was done in an era when the 
prevalence of coeliac disease in the population was thought to be much less 
than it was later shown to be, following the advent of reliable serological 
screening tests.   
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More accurate estimates of malignancy in coeliac disease (8) 
In order to minimise the hazards of selection bias, a 24-year prospective, 
population-based cohort study of malignancy in diagnosed patients with 
coeliac disease was undertaken (8). For this investigation, data from the Derby 
coeliac disease register that I had compiled was utilised. All patients with 
coeliac disease diagnosed by small bowel biopsy and followed prospectively 
from 1978 to the end of 2001 were included in the study. This cohort of 
patients from a single centre in Southern Derbyshire was unique in studies of 
malignancy in coeliac disease, as it represented all cases occurring in a well-
defined geographical area and follow-up was 99% complete. Referral bias is 
unlikely to have affected the results because Derby is not a tertiary referral 
centre for gastrointestinal diseases and patients in the study all derived from 
Southern Derbyshire. In addition, to avoid case ascertainment only 
malignancies occurring 2 or more years after the diagnosis of coeliac disease 
were considered in the main analysis. This was termed the post-diagnosis 
period. There were 637 patients with time to contribute to the analysis 
amounting to 5684 patient years of follow up (8) [Table 1]. Thirty-one 
malignancies (excluding non-melanoma skin cancer) were found when 30.30 
were expected, so there was no increase in the overall cancer risk (SIR 1.02 
95% CI 0.70-1.45). The risk for non-Hodgkin's lymphoma was elevated (SIR 5.80 
95% CI 1.58-14.86). One lymphoma originated in the small bowel (SIR 40.51 
95% CI 1.03-225.68) [Table 4]. This was the first time that an estimate for small 
bowel lymphoma in coeliac disease compared with the general population had 
been arrived at, presumably because other groups had no relevant population 
data to make the comparison. We used estimates generated by the West 
Midlands Cancer Intelligence Unit, which are likely to be robust because of 
validation of each registered case of lymphoma by reference to original case 
notes. This study also drew attention to the rarity of enteropathy-associated T-
cell lymphoma, a tumour particularly linked to coeliac disease.  Of 5 non-
Hodgkin's lymphomas occurring in the period within 2 years of the diagnosis of 
coeliac disease, the peri-diagnosis period, only 3 were enteropathy-associated 
T-cell lymphomas [Table 4]. Small intestinal carcinoma was also shown to be a 
rare association, with only 1 occurrence.  
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This overall risk for lymphoma is lower than previous estimates because of 
improved study design and reflects results from other investigations carried 
out at about the same time. In a study from Italy a relative risk for all non- 
Hodgkin's lymphoma was found to be 3.1, 16.9 for gut lymphoma and 19.2 for 
T-cell lymphoma (9). Only one patient with enteropathy-associated T-cell 
lymphoma was encountered. 
European study of non-Hodgkin lymphoma in coeliac disease (10) 
A large series of patients was required to confirm these findings and in order to 
achieve this a prospective, multicentre case-control study involving 12 working 
groups in 10 European countries was set up (10). This was supported by a grant 
from the Biomed-2 programme of the European Union. I travelled to Brussels 
with a colleague from the Netherlands to present the case to the Health 
Commissioner for carrying out the study which was accepted.  
A total of 1446 patients with non-Hodgkin's lymphoma and 9655 controls 
recruited between May 1998 and April 2001 were screened for endomysial 
antibodies to detect coeliac disease and those found positive were offered a 
small bowel biopsy to confirm the diagnosis (10) [Figure 2]. It was found that 
patients with coeliac disease had a significantly increased risk of developing 
non-Hodgkin's lymphoma (OR 2.6 95% CI 1.4-4.9) [Table 2]. This risk was only 
present in those diagnosed clinically (OR 3.3 95% CI 1.4-7.9) but not in those 
with silent coeliac disease (OR 1.3 95% CI 0.6-2.7). Only 8 patients with 
enteropathy-associated T-cell lymphoma were identified which again 
highlighted the rarity of this tumour [Table 4]. This study emphasised the value 
of collaborative working because individual centres may not be able to recruit 
enough cases to draw valid conclusions. It was favourably reviewed by an 
expert in coeliac disease research and the finding that those detected by 
screening do not have an increased risk of lymphoma was particularly 
commented on (11). It was all regarded as good news and reassuring for 
patients. 
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Non-lymphoma malignant complications of coeliac disease (12) 
It was evident in early studies of coeliac disease that associated malignancy 
was not confined to lymphoma although this was given prominence. Certain 
gastrointestinal carcinomas, notably those of the oesophagus, pharynx and 
small intestine have also been linked (4, 5). We encountered 4 patients with 
adenocarcinoma of the  upper small bowel in patients with coeliac disease and 
a review of the literature in 1980 revealed that only 14 others had been 
reported at that time (12). It was surprising that there were so few reports as 
this part of the bowel is characteristically abnormal in untreated coeliac 
disease with histological features of premalignancy (13). It was not possible 
from the study to say what the risk was of developing this tumour. Nearly all 
patients come to surgery and if the tumour is diagnosed early before it has 
metastasised, cure may be possible with long survival.  
In the early 1980s a survey of coeliac disease and malignancy was undertaken 
(14). Twenty centres in the UK with an interest in coeliac disease were asked to 
report their experience. Overall, 133 lymphomas, 19 adenocarcinomas and 10 
oesophageal carcinomas were encountered. The average number of tumours 
seen at each centre equates to 6.7, 0.95, and 0.5, respectively. These figures 
illustrate how rare these are, a fact curiously largely overlooked at that time.  
Primary small bowel malignancy associated with coeliac disease (15) 
Under the auspices of the British Society of Gastroenterology, I along with 3 
other colleagues undertook a survey of small bowel malignancy in the UK and 
its association with coeliac disease (15). Clinicians in the UK registered with the 
British Society of Gastroenterology were asked using cards mailed out every 
month, to report newly diagnosed cases of primary small-bowel malignancy 
that they had encountered between June 1988 and May 2000. Following 
notification of a case further details were requested including demographic, 
clinical and pathological information and in particular whether coeliac disease 
was present or not. Telephone contact was made with clinicians to clarify 
details if deemed necessary. This was a very successful venture, for 395 cases 
including 175 adenocarcinomas, 107 lymphomas and 79 carcinoid tumours 
were reported. In 13% (23 of 175) of adenocarcinoma cases and 39% (42 of 
24 
 
Sensitivity: Internal 
107) of lymphomas there was a diagnosis of coeliac disease [Table 1]. 
Adenocarcinomas (94%) and lymphomas (80%) associated with coeliac disease 
were in the proximal small bowel as might be expected because this is the part 
of the small intestine damaged in untreated coeliac disease. As expected most 
of the lymphomas (89%) were enteropathy-associated T-cell type, an entity 
first described in 1986 (16).  About half of patients with these tumours 
presented acutely with features such as intestinal obstruction, haemorrhage or 
perforation. At the time of diagnosis about a half of patients with 
adenocarcinomas and a third with lymphomas had widespread metastatic 
disease resulting in a poor prognosis. The overall survival for those with 
adenocarcinomas was 58% at 30 months but for those with widespread 
disease was only 35% [Figure 1]. There was no evidence that having coeliac 
disease worsened the outlook. For patients with lymphoma the overall survival 
was 45% at 30 months but for those with advanced disease it was only 30%. 
The prognosis for those with coeliac disease was particularly poor with a 30 
month survival of only 13 % compared with 52% for those without [Figure 3].  
This national survey was one of the first such to be carried under the auspices 
of the British Society of Gastroenterology and resulted in the largest number of 
small intestinal malignancies reported in one series. It showed that there are 
clearly advantages in ascertaining cases of a rare disease through a central 
data base. Individual departments specialising in the diagnosis and 
management of coeliac disease, even large ones, do not encounter small 
bowel malignant tumours in sufficient numbers to draw any valid conclusions 
regarding their frequency and natural history. In this study over a 2 year 
period, 395 events, a commendably large number, were recorded for analysis. 
Such a scheme does have potential disadvantages. There may be under 
reporting but the number of tumours actually reported, accorded with the 
numbers predicted by data from the Derby coeliac clinic. Using the data from 
Derby, 55 lymphomas and 22 adenocarcinomas of the small bowel would be 
expected to occur in the UK during the 2 years of the survey. Given that 42 
lymphomas and 23 adenocarcinomas were ascertained, suggested that 
reporting reflected the national expected incidence rate of small bowel 
malignancy associated with coeliac disease. The survey provided evidence that 
small bowel tumours are rare in the UK and in particular that the risk to coeliac 
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patients developing malignancy is very low. These data were reassuring for 
patients and their carers.   
Reviews of malignant complications 
I have authored or co-authored several publications in journals or books that 
have reviewed knowledge of the malignant complications of coeliac disease as 
it has become available. These were often commissioned and spanned the 
years 1974-2014. 
The earliest one on malignant complications published in 1974 was an attempt 
to summarise the sparse research that had been carried out to that date. It 
was recognised that the development of malignancy was a very serious 
problem with a poor prognosis, which was difficult to diagnose and for which 
there was no effective treatment. In particular, whether giving a gluten free 
diet to patients would reduce the lymphoma risk was not known (17).  
A second article was published in 1978, based on a lecture that I gave to the 
Third International Symposium on Coeliac Disease held in Galway, Ireland in 
1977. The clinical features of 27 patients with lymphoma who had attended 
the Department of Gastroenterology at the General Hospital Birmingham, 
were reviewed. Two thirds were diagnosed at laparotomy or autopsy. The 
appalling prognosis of patients who developed lymphoma was evident and 
measured in months. There was no effective treatment and still no evidence 
that a gluten free diet protected against the development of lymphoma (18).  
A chapter that I co-authored in 1992 was a comprehensive account of the 
subject up to that time and covered clinical, diagnostic and pathological 
aspects (19). It contained many illustrations of the gross appearance of 
tumours and histological findings. The intriguing connection, not fully worked 
out then, between bowel lymphoma and chronic ulceration of the small 
intestine was also highlighted. The protective role of a gluten free diet in 
preventing the development of lymphoma was becoming apparent and was 
emphasised.   
Two further reviews in the 1990s were constructed along similar lines and 
designed to keep readers up to date (20, 21). There was growing interest in the 
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cellular origins of lymphoma, the role of intraepithelial lymphocytes in the 
development of enteropathy-associated T-cell lymphoma (the characteristic 
lymphoma that complicates coeliac disease) and genetic markers in coeliac 
disease and enteropathy-associated T-cell lymphoma and these were 
summarised in a later review that also included a discussion of non-responsive 
coeliac disease and its relationship to lymphoma which was becoming better 
defined  (22).  
In 2005, I co-authored a major review of malignancy in coeliac disease 
commissioned by the American journal, Gastroenterology, which is the most 
prestigious gastroenterology journal in the world (23) . By this time, important 
epidemiological studies had been published which showed that while coeliac 
disease is significantly associated with an increased risk of non-Hodgkin 
lymphoma, especially of the T-cell type and primarily located in the bowel, the 
link is less common than previously supposed with a relative risk of about 3. In 
addition, much evidence was accumulating to show that a gluten free diet was 
beneficial in reducing the risk of lymphoma from developing.  
Non malignant associations 
Coeliac disease is common so that other disorders will occur in association 
from time to time. Some of these will occur only by chance but others will have 
a statistically valid relationship. Those caring for coeliac patients need to aware 
of these links so that patients receive optimum treatment. Twenty-one 
publications that I have authored or co-authored are included in this section.  
 Autoimmune disorders 
Early reports including small numbers of patients drew attention to coexistent 
disorders with known or suspected immunological aetiology. It was speculated 
that circulating immune complexes originating in the damaged mucosa or the 
passage of antigens across the permeable small bowel mucosa might trigger 
the development of these associations. We decided to analyse a large number 
of biopsy proven patients with coeliac disease diagnosed between 1958 and 
1977 at the General Hospital Birmingham, with regard to immunological 
disorders (24). Of 314 patients considered, 63 had associated disorders of 
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known or suspected immunological cause. The most common disorders 
encountered were diabetes mellitus, thyroid disease and ulcerative colitis 
[Table 1]. Other disorders found were connective tissue disease, chronic liver 
disease and diffuse lung disease. Twenty three atopic disorders were found in 
22 patients.  One women had eczema and one asthma. A gluten free diet and 
near normal jejunal biopsy did not prevent the development of these 
associations and had no effect on their course. Weaknesses are easy to identify 
in this survey. Information was obtained from direct interview with patients 
and by review of hospital notes when this was not possible. Only when there 
was a definite diagnosis of a disorder was this counted, although it is likely that 
there was an underestimation if information had not reached the notes or 
patients had failed to mention or forgotten about a diagnosed association. No 
firm conclusions could be drawn from these data regarding the frequency of 
the associations because the incidence of coeliac disease in the community 
was not known and that of immune disorders even less so. Nevertheless, 
interesting data were gleaned from this study and it pointed the way to future 
research.  
 Inflammatory bowel disease 
There was an indication in the previous study that ulcerative colitis was 
commonly associated with coeliac disease with numbers possible greater than 
expected (24). From the Gastrointestinal Unit at the General Hospital 
Birmingham, 4 patients were reported having associated coeliac disease and 
inflammatory bowel disease, 3 with ulcerative colitis and 1 with Crohn's 
disease (25). Taking into account the prevalence of inflammatory bowel 
disease in the community at 96-190 cases per 100,000 and that 420 patients in 
the unit were surveyed, the observed prevalence in the series would be 5-10 
times than expected. However, the patients were derived from a referral 
centre for inflammatory bowel disease and coeliac disease so were from a 
selected group. The main reason for reporting these cases was to encourage 
others to identify additional examples and so perhaps clarify better the nature 
of the association. 
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Diabetes mellitus 
It appeared that diabetes mellitus was the disorder most commonly associated 
with coeliac disease and worthy of further research. In 1984, I undertook a 
search for relevant publications for a chapter in a book on coeliac disease that I 
co-authored and was able to find 28. Nineteen of these included jejunal biopsy 
proven cases and in 14 patients had shown clinical and/or biopsy improvement 
on gluten free diet (26). This was the most commonly reported disorder 
associated with coeliac disease. At that time there was not enough evidence to 
state whether the association was more than could be accounted for by 
chance.   
Because of the paucity of information in adults, we set up a study to determine 
the prevalence of coeliac disease in an unselected hospital-based adult 
diabetic population using IgA-antigliadin antibody (AGA) screening followed by 
endoscopic duodenal biopsy. In addition, whether those with coeliac disease 
had compatible symptoms of malabsorption was assessed and their 
acceptance of and response to a gluten free diet documented (27). A total of 
1785 diabetic patients were screened between April 1st 1992 and March 31st 
1993. 43% had insulin dependent diabetes mellitus (IDDM) and 57% non-
insulin dependent diabetes mellitus (NIDDM). Of those screened, 73 had raised 
IgA-AGA and 8 selective IgA deficiency. Duodenal biopsies were performed in 
49 patients with raised IgA-AGA of whom 10 with IDDM and 3 with NIDDM had 
small bowel histology compatible with coeliac disease. Twenty-four patients 
for various reasons did not have endoscopy. One of those with selective IgA 
deficiency also had coeliac disease so in total 14 new patients with coeliac 
disease were identified [Figure 1]. Of these, 4 had microcytic anaemia, 9 low 
serum ferritin and 4 low albumin-corrected calcium. Eight had gastrointestinal 
symptoms or chronic fatigue that improved on gluten free diet and 6 were 
asymptomatic. In addition during the study we encountered 4 patients, all 
IDDM, with known coeliac disease. The overall prevalence of coeliac disease in 
diabetes was 1:100 (18 in 1789). In adult IDDM it was 1:50 compared with 
1:340 for NIDDM. Coeliac disease is common in IDDM and may cause 
malabsorption and ill-health that is corrected by gluten free diet. These figures 
may be underestimates of the true prevalence because it was assumed that 
29 
 
Sensitivity: Internal 
patients who were not endoscoped did not have coeliac disease. Overall 
diabetic control did not change with the adoption of gluten free diet, although 
our patients did not experience hypoglycaemia and their diabetes was stable.  
Based on these figures, our data suggested that at that time 2500 in England 
and Wales would have coexistent coeliac disease with about 1800 not 
diagnosed. It was emphasised that symptoms in these patients may be wrongly 
attributed to diabetes, so the diagnosis of coeliac disease may not be 
considered which is unfortunate because a gluten free diet can restore full 
health. It was shown that screening for coeliac disease is possible and may be 
worthwhile. Our results began a debate on this aspect of management for 
these patients.  
Reviews of the association between coeliac disease and diabetes 
Based on my interest in coeliac disease with co-existing diabetes mellitus I was 
asked to write three reviews. The first summarised what was known about the 
relationship between coeliac disease and Type 1 diabetes mellitus with 
emphasis on the prevalence of coeliac disease in diabetes in adults and 
children, possible reasons for the association, clinical presentations, the value 
of gluten free diet, implications for the control of diabetes and implications of 
screening programmes (28). Twenty papers exploring the prevalence of coeliac 
disease by serological screening of Type 1 diabetes in children, 8 in adults and 
2 including both groups were found. An additional 48 publications were 
included and were related to serological screening for coeliac disease, 
expressions and complications of coeliac disease, the value of gluten free diet 
and the genetics of the two conditions. It was evident that more recent studies 
were now employing the more sensitive and specific screening tests looking for 
endomysial and anti-tissue transglutaminase antibodies.   
Unless screening of patients with diabetes is undertaken coeliac disease will be 
missed, because patients often have atypical symptoms or none and even in 
those with classical symptoms the diagnosis may be overlooked and attributed 
wrongly to diabetes. Based on biopsy proven coeliac disease the prevalence of 
Type 1 diabetes in children in these publications was 1:6 to 1:103 and in adults 
1:16 to 1:76. So the association occurs commonly. Following the institution of 
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gluten free diet, patients may improve in terms of symptoms, growth in 
children, serum antibody levels, haematological and biochemical indices, 
morphology of the small bowel mucosa and control of diabetes. It was 
recommended that screening for coeliac disease should be undertaken and 
was cost effective. It was clear from the various series that a single screening is 
not enough because tests previously negative can become positive. In the 
absence of firm evidence, it was suggested that it would be prudent to screen 
at the diagnosis of diabetes and annually for 3 years, then at 5 years and then 
5 yearly thereafter, or at any time if there are clinical indications. 
The second invited review came from a paediatric journal (29). The average 
prevalence of coeliac disease among children with diabetes mellitus in 26 
reports then available was 4.5%. There were a number of questions to 
consider. Will health benefits accrue in children in terms of resolution of 
symptoms, a reduction in complications associated with coeliac disease and 
improved control of diabetes if given a gluten free diet? Is one test enough and 
if not, when should subsequent tests be carried out? Is a screening programme 
cost effective when compared with other screening programmes, for example, 
for congenital hypothyroidism, cystic fibrosis and phenylketonuria? All these 
issues were discussed in the review. It was easy to make a case for screening 
given the high frequency of the association, the availability of high performing 
screening tests, on economic grounds and that intervention with gluten free 
diet can improve health and avoid complications. Indeed, many paediatricians 
were already screening and this practice was subsequently endorsed in 
guidelines published by the European Society for Pediatric Gastroenterology, 
Hepatology and Nutrition (ESPGHAN) published in 2012 (30). A helpful 
algorithm was presented that set out a strategy that should be followed. Our 
work was referenced in these guidelines and contributed to a reconsideration 
of the diagnostic criteria for diagnosing coeliac disease. 
The last commissioned review published in 2015 on this association, was aimed 
at nurses (31). It was concluded that although there is still much to unravel on 
this subject, enough is already known to guide health care workers in the 
diagnosis and management of people with associated coeliac disease and type 
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1 diabetes and that it was incumbent on practitioners to be aware of this link 
so that patients receive optimal care and enjoy good health.  
 Neurological and psychiatric disorders 
Neurological disorders associated with coeliac disease was a special interest of 
the Gastroenterology Department at the General Hospital, Birmingham and in 
1966, 2 influential papers were published that documented 16 patients 
encountered, 9 of whom had autopsies. Clinical details and pathological 
findings were described in detail. The aetiology of the association was 
unknown and the outlook for these patients was very poor (32, 33). I 
continued with this interest and co-authored a report of 4 patients with coeliac 
disease who had developed neurological complications (34). Unfortunately, 
there had been no advances in understanding of this condition since the 
original paper nearly 30 years previously.  
In 1997, I was invited to speak at a symposium on Epilepsy and other 
Neurological Disorders in Coeliac Disease held in San Marino. My title was 
neurological and psychiatric complications in coeliac disease and the 
contribution appeared in a book of the proceedings that same year (35). For 
this occasion, I reviewed these problems in 388 unselected patients with 
coeliac disease in my own clinic in Derby. In total 106 patients (26%) developed 
132 neurological or psychiatric problems; several patients had more than one 
disturbance [Table 1]. Since patients were unselected and drawn from the local 
area, these data were likely to reflect the numbers and types of neuro-
psychiatric disorders that occur in the community. Many of the disorders were 
only encountered as single cases but depression, epilepsy and migraine were 
well represented and the three commonest problems recorded. Depression 
affected 10% of the group and while it is an important feature in some 
instances, it is not certain whether it is more common in coeliac disease than 
the general population. Epilepsy did seem more common in coeliac disease at 
3.6% for a prevalence in the population of about 0.5%. The prevalence of 
migraine at 3.1% was the same as in the community. Although care was taken 
only to include disorders for which there was good evidence, caution has to 
exercised in interpreting these results because it can be difficult to define 
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these conditions with certainty and an added problem is that the prevalence in 
the population is difficult to determine.  
We prepared a review for the Postgraduate Medical Journal on the 
neurological complications of coeliac disease which was published in 2002 (36). 
For this the experience of the Derby coeliac clinic was brought up to date. We 
found 263 neurological and psychiatric conditions in 189 (30%) patients out of 
620 with coeliac disease (some patients had more than one condition) [Table 
1]. This was a similar proportion to that found in the earlier study and again 
the commonest associated conditions were depression (11.5%), epilepsy 
(4.0%) and migraine (3.2%). Whether a specific neurological disorder occurs in 
coeliac disease remained unproven. Malabsorption did not satisfactorily 
explain the pathophysiology and it was considered that autoimmunity, 
heredity and gluten toxicity might have a role. In 2004 this review was 
reproduced in a book along with others that the editor referred to as 
outstanding (37). We looked in more detail at the prevalence of epilepsy in a 
large group of 801 unselected coeliac patients attending my clinic in 2004 and 
the condition did not appear to be significantly more common among these 
than in the population (38). Some other studies did find an association but 
conclusions were based on small numbers of patients. 
 Osteoporosis and bone metabolism 
Coeliac disease has long been known to cause metabolic bone disease both 
osteomalacia secondary to calcium and vitamin D malabsorption and 
osteoporosis (39). Osteoporosis as determined by non-invasive dual-energy X-
ray absorptiometry (DEXA) is common in coeliac disease affecting about half of 
patients and predisposing to fracture. However, because the magnitude of the 
risk was unknown we surveyed a population of patients recruited from Derby 
and Nottingham with coeliac disease (244 patients and 161 controls) to assess 
this. No overall increased fracture risk was found in this study, the largest to 
that date (40). A later meta-analysis found only a moderate fracture risk (41). 
The results indicated that surveillance by DEXA scanning was not warranted in 
general for osteoporosis, although subpopulations such as elderly women, 
those with a family history of osteoporosis, previous fractures and poor 
adherence to gluten free diet should be checked (42).   
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 Mesenteric lymph node cavitation syndrome 
I first encountered a patient with this condition in 1982. Coeliac disease had 
been diagnosed in childhood in 1944. In 1982, he was referred to me very ill. 
Masses could be felt in the abdomen. It was feared that he had developed 
malignant lymphoma but at laparotomy large, multiple, tense cysts were found 
in the intestinal mesentery, the largest being 8 cm in diameter. The cysts were 
decompressed and after a stormy postoperative period he made a full recovery 
and was re-established on a strict gluten free. This very rare syndrome had 
previously been reported in the French literature but only in a handful of 
patients. My paper was the first to report this in English (43). The importance 
of the syndrome is that it may be mistaken for lymphoma or other cancerous 
growths in the abdomen although it is a benign condition and amenable to 
treatment.  
Reviews of non-malignant complications 
With regard to long-term health risks and non-malignant complications, I have 
authored or co-authored 8 invited reviews which have appeared in journals or 
as book chapters. The first was published in 1992 and drew attention to 
problems associated with fertility and pregnancy, disturbances of bone and 
calcium metabolism and neurological and psychiatric disturbances, all of which 
were increasingly being recognised around that time (44). A further review was 
commissioned 4 years later when I was able to report in much more detail on 
all these and other aspects. It was emphasised that the diagnosis of coeliac 
disease was crucial because a gluten free diet not only improves the general 
health of patients but may positively influence the development and progress 
of these associations (45). Other reviews have already been mentioned and 
contained new information from my Derby coeliac disease clinic as outlined 
above (36, 37, 46).  
On the strength of our interest in the neurology of gastrointestinal disorders 
we were invited to contribute an editorial to the Journal of Neurology, 
Neurosurgery and Psychiatry which was published in 2006. This editorial had a 
wider remit than just coeliac disease and covered neurological complications 
of gastrointestinal, hepatic and pancreatic disease in adult patients (47). The 
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role of liver failure in the development of neuropathology was well established 
but for other enteric diseases, whether any specific disorders occur remained 
unproven. 
In 2010 and 2014, a colleague and I published  major  reviews of the risk of 
morbidity in contemporary coeliac disease, one in a journal (48) and the other 
as a book chapter running to 34 pages and 263 references (49). Many good 
studies were available of disorders occurring with coeliac disease that gave 
accurate estimates of the risk of the associations. It was concluded that those 
who care for coeliac patients need to be aware of these associations so that 
optimal management can be given. These are probably the most 
comprehensive accounts to date.  
 Malignant and non-malignant deaths in the serology era 
The introduction of serological tests to aid the diagnosis of coeliac disease in 
the early 1990s led to more and more diagnoses being made (50, 51). Many, 
perhaps even most of these would not have been diagnosed in the pre-
serology era because of so-called atypical or mild symptoms that may not have  
indicated coeliac disease as a potential diagnosis. An unanswered question was 
whether patients diagnosed in the serology era with less severe disease, 
experienced excess mortality and if so what was the magnitude of the risk. 
Most studies that had been carried out contained relatively small numbers of 
patients and gave contradictory results.  
In order to address this issue Derby coeliac patients were stratified according 
to the year of diagnosis; (i) before 1990, (ii) between 1990 and 1999, and (iii) 
from 2000 onwards (50). These periods reflected the increasing use of 
serological tests to detect the condition. For this exercise only incident cases 
were considered i.e. those diagnosed after January 1978. There were 987 such 
individuals contributing 7,431 person-years beyond 2 years after the diagnosis 
of coeliac disease (post-diagnosis period) [Table 4]. Over the time of the study 
there was an exponential year-on-year increase in the number of diagnoses 
being made in the Derby Hospitals [Figure 1]. The number of diagnoses was 
eight-fold higher in 2001-2005 compared with 1981-1985. Patients diagnosed 
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solely by serology were not considered. Overall, there was no trend towards 
increased or reduced mortality with a more recent diagnosis [Table 4].  
To the end of 2006, 1,285 individuals were diagnosed with coeliac disease in 
Derby of whom 1,092 had follow-up beyond 2 years after the diagnosis of 
coeliac disease (post-diagnosis period) and were available for analysis. In this 
group were 142 deaths which represented a statistically significant increase 
from all causes compared with the general population of England and Wales 
(SMR=1.37; 95% CI 1.16-1.62) [Tables 1 and 2]. Raised risks were found for 
respiratory (not significant) and gastrointestinal disease (significant). When the 
risks were compared with those in the peri-diagnosis period (within 2 years of 
the diagnosis of coeliac disease), the increase in mortality was similar 
(SMR=1.31; 95% CI 0.89-1-84), significantly increased for men (SMR=1.86 95% 
CI 45-2.34) but not for women. Deaths from cancer and gastrointestinal 
disease were more pronounced than in the post-diagnosis period. [Table 2]. 
Overall there was a marked increase in deaths from non-Hodgkin's lymphoma 
(SMR=7.06; 95% CI 2.59-15.4) [Table 3]. Over half of the deaths due to 
respiratory causes (11 of 21) were due to pneumonia although the risk of 
death was not statistically significant [Table 3].  
The results showed no evidence of a reduction in mortality associated with 
coeliac disease diagnosed in the most recent decade, and the magnitude of the 
overall increased risk was only modest. It might have been expected that the 
risk would have decreased, because in the serology era milder cases of coeliac 
disease would be diagnosed with risks more akin to the general population but 
this was not confirmed.  
A key strength of this study is that it is truly population based and therefore 
unlikely to be biased in the selection of cases. There were over 10,000 person-
years of data and 142 deaths in the postdiagnosis period for analysis. 
Furthermore, in contrast to most other studies, it covered the period before 
and after the introduction of serological tests and allowed time trends in 
mortality in relation to this. It was possible to examine the risk of death from 
pneumonia and liver disease. The interest in coeliac disease in Derby will have 
contributed to the high numbers of patients diagnosed but if anything this 
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should have led to less symptomatic patients being diagnosed and a reduced 
mortality rate that we sought but it did not.  
In this study it was possible to perform a time stratified analysis. Most other 
studies at the time could not do this because their data did not cover the pre 
and post serology eras. By doing this we produced important information for 
clinicians which showed that there remains an increased relative risk of death 
from lymphoma but the overall mortality increase is modest so that patients 
can be reassured. It was suggested that further research into deaths from liver 
disease and pneumonia was warranted and greater consideration should be 
given to vaccinating against pneumococcal infection which might reduce 
mortality.  
It was envisaged that results from this study would be updated when more 
diagnoses had been made and there were more deaths to consider and using 
similar methodology. This was undertaken and included patients with coeliac 
disease diagnosed to the end of 2014 (51). At this time there was a total of 
2515 patients of whom 750 were diagnosed by serological tests alone. 2174 
patients in the series had at least 2 years of follow-up (postdiagnosis period) 
and contributed 23955 person-years of follow-up. The median duration of 
follow-up had risen from 6.2 to 9.3 years [Table 1]. The mean age at baseline 
was older for all patients at 46.1 years, compared with 45.6 years previously 
and in those with at least 2 years of follow-up at 45.5 years compared with 
44.8 years previously. There were 284 deaths [Table 1]. So there was much 
more data available for this new analysis.  
Table 2 shows that the SMR for all deaths in the postdiagnosis period was now 
1.57 compared with 1.37 previously. Taking the confidence intervals into 
account, this is a fractional increase without real significance but could be as 
much as 77% more deaths in this population compared with 62% in the 
previous study. There were significant increases in deaths for all categories 
studied except for cardiovascular disease which fell just short of significant. Of 
interest, in the peridiagnosis period, the SMR reduced in all instances apart 
from cardiovascular disease.  
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When individual causes of death were analysed for the postdiagnosis period 
there was an increase for non-Hodgkin's lymphoma (SMR 6.32; 95% CI 2.89-
12.0) [Table 3]. Breast cancers were non-significantly reduced. No increase or 
decrease for cancer of the lung was observed. Deaths from pneumonia were 
significantly increased (SMR 2.58; 95% CI 1.66-3.85) and those from liver 
disease (SMR 3.10; 1.34-6.10) [Table 3]. A significant increase was found for 
oesophageal cancer (SMR 2.8; 95% CI 1.03-6.08). No changes for uterine or 
ovarian tumours occurred.   
In this new study, the SMR for deaths after 1 January 2000 has fallen to 1.60 
(95% CI 1.32-1.92) from SMR 2.23 (95% CI 1.83-2.70) between 1 January 1990 
and 31 December 1999. This is only marginally insignificant. In the previous 
study there was no trend towards increased or reduced mortality. However, in 
this new investigation, there was for the respiratory group - SMRs of 1.34 > 
2.50 > 2.85 [Table 4]. In other disease areas, risks were greatest during the 
1990 to 1999 period but reduced post 2000, which follows the same findings as 
in the earlier study.  
Previously, the overall mortality risk among people with coeliac disease was 
14.0 per 1,000 person-years compared with 10.2 in the general population. 
New figures were 11.9 compared with 10.5, giving an absolute risk difference 
of 1.4 per 1.000 person-years compared with 3.8 previously. This has reduced 
by more than half [Table 5]. There was no difference in the attributable risk 
between causes related to and not related to coeliac disease. Previously, 34% 
of the overall difference in risk was attributed to coeliac disease deaths while 
66% was not. In the new study it was 50/50. This suggests that the differences 
in risk attributed to coeliac deaths (non-Hodgkin's lymphoma, pneumonia or 
coeliac disease) is growing. 
A strength of this new study is that it analysed a substantial number of non-
selected patients with coeliac disease attending a single centre in Southern 
Derbyshire and the outcome for these was complete for 99.8% of cases. 
Ascertainment bias was minimised by excluding the first 2 years of follow-up 
after the diagnosis of coeliac disease. Patients diagnosed by serological tests 
alone using validated criteria were included. To have ignored these would have 
removed some 30% of patients from consideration which would have distorted 
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the results. It can be speculated that including these cases has impacted on the 
risk of mortality on the cohort as a whole. According to these data there is an 
opportunity to improve survival by implementing vaccination programmes for 
pneumonia and more prompt and aggressive treatment of liver disease.  
Conclusions 
The publications presented, form a body of research that I have been involved 
with on the theme of morbidity and mortality in coeliac disease covering the 
years 1974 to 2018 – a 45 year period. When I began my research at the start 
of this era, little or nothing was known about conditions leading to morbidity 
and mortality. I designed my research agenda to try and correct gaps in 
knowledge with I believe, some success.  
In this thesis, I have presented 35 publications, 14 devoted to malignant and 21 
to non-malignant associations and complications, covering a wide spectrum of 
conditions including lymphoma and non-lymphoma malignancy, inflammatory 
bowel disease, diabetes mellitus, thyroid disease, neurological and psychiatric 
disorders and disturbances of bone. My publications on malignant 
complications particularly lymphoma have been ground breaking, well 
received and widely quoted. My paper, Malignancy in coeliac disease – effect 
of a gluten free diet published in the journal Gut in 1989, was the most quoted 
paper in the year of publication for that journal. It has been cited over 1120 
occasions. More recently I have provided in the final paper, risk estimates for 
various disorders causing death in contemporary coeliac disease and have 
indicated how reduced mortality might be achieved in some instances. My 
publications on associated diabetes mellitus have also been referred to quite 
widely. For 24 papers where information exists, the total number of citations 
stands at almost 3,900. This excludes references to my book chapters.  
In recent years with the development of methods to identify patients with 
coeliac disease and more sophisticated approaches to epidemiology, reliable 
data on conditions contributing to morbidity and mortality in coeliac disease 
have emerged. My research activity reflects this evolution and I believe has 
influenced it. It has been an exciting and rewarding time to be exploring these 
issues for the benefit of patients, their families and carers.  
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